Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Diffuse Large B-Cell Lymphoma's New Genomics: The Bridge and the Chasm

Diffuse Large B-Cell Lymphoma's New Genomics: The Bridge and the Chasm review articles Diffuse Large B-Cell Lymphoma’s New Genomics: The Bridge and the Chasm 1 1 Jennifer L. Crombie, MD and Philippe Armand, MD, PhD 2,7 INTRODUCTION stratification tool for DLBCL and has spawned sev- 8,9 eral variants. Yet despite its powerful and re- The clinical and molecular heterogeneity of diffuse producible prognostic value, it has not, with few large B-cell lymphoma (DLBCL), even beyond the 10,11 1 exceptions, translated into therapeutic stratifica- recent WHO reclassification, is well recognized. (For tion likely because it does not align directly with the simplicity, this review will still use the term DLBCL to molecular heterogeneity of DLBCL. Indeed, in all the cover all the related WHO entities, including high- major classification studies, old and new, the genomic grade B-cell lymphoma [HGBL].) Yet, efforts to in- classification’s prognostic value is complementary, dividualize therapy on the basis of this recognition 2,3 and not substitutable, to that of the IPI. have thus far been met with limited success. Why this may be, and why this may soon change, is the The first major step toward deciphering the genomic topic of this review. Recent comprehensive multi- complexity of DLBCL was taken through the inven- platform genomic analyses http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Clinical Oncology Wolters Kluwer Health

Diffuse Large B-Cell Lymphoma's New Genomics: The Bridge and the Chasm

Download PDF
11 pages

Loading next page...
 
/lp/wolters-kluwer-health/diffuse-large-b-cell-lymphoma-s-new-genomics-the-bridge-and-the-chasm-rQ4DpcYvsT

References (85)

Publisher
Wolters Kluwer Health
Copyright
(C) 2020 American Society of Clinical Oncology
ISSN
0732-183X
eISSN
1527-7755
DOI
10.1200/JCO.20.01501
Publisher site
See Article on Publisher Site

Abstract

review articles Diffuse Large B-Cell Lymphoma’s New Genomics: The Bridge and the Chasm 1 1 Jennifer L. Crombie, MD and Philippe Armand, MD, PhD 2,7 INTRODUCTION stratification tool for DLBCL and has spawned sev- 8,9 eral variants. Yet despite its powerful and re- The clinical and molecular heterogeneity of diffuse producible prognostic value, it has not, with few large B-cell lymphoma (DLBCL), even beyond the 10,11 1 exceptions, translated into therapeutic stratifica- recent WHO reclassification, is well recognized. (For tion likely because it does not align directly with the simplicity, this review will still use the term DLBCL to molecular heterogeneity of DLBCL. Indeed, in all the cover all the related WHO entities, including high- major classification studies, old and new, the genomic grade B-cell lymphoma [HGBL].) Yet, efforts to in- classification’s prognostic value is complementary, dividualize therapy on the basis of this recognition 2,3 and not substitutable, to that of the IPI. have thus far been met with limited success. Why this may be, and why this may soon change, is the The first major step toward deciphering the genomic topic of this review. Recent comprehensive multi- complexity of DLBCL was taken through the inven- platform genomic analyses

Journal

Journal of Clinical Oncology – Wolters Kluwer Health

Published: Oct 20, 2020

There are no references for this article.